Table 2.
Taxane group | S-1 group | |||||
---|---|---|---|---|---|---|
Expected response | Completed response (%) | Mean (SD) | Expected response | Completed response (%) | Mean (SD) | |
Health utility, months | ||||||
0 | 174 | 174 (100.0) | 0.766 (0.156) | 206 | 206 (100.0) | 0.768 (0.166) |
3 | 151 | 137 (90.7) | 0.773 (0.153) | 167 | 145 (86.8) | 0.813 (0.160) |
6 | 95 | 86 (90.5) | 0.753 (0.160) | 119 | 105 (88.2) | 0.806 (0.166) |
12 | 33 | 29 (87.9) | 0.784 (0.184) | 67 | 60 (89.6) | 0.848 (0.159) |
Global health status, months | ||||||
0 | 174 | 174 (100.0) | 61.2 (22.4) | 206 | 206 (100.0) | 59.3 (22.0) |
3 | 151 | 140 (92.7) | 62.0 (22.7) | 167 | 145 (86.8) | 64.7 (20.3) |
6 | 95 | 86 (90.5) | 58.1 (23.7) | 119 | 105 (88.2) | 64.0 (24.2) |
12 | 33 | 29 (87.9) | 59.5 (23.5) | 67 | 59 (88.1) | 64.5 (24.2) |
The number of expected responses at each assessment point was calculated by subtracting the number of patients after the end of the study treatment from the number of patients included in the present study
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, SD standard deviation